Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Rutgeerts, K. Geboes, M. Peeters, M. Hiele, F. Penninckx, R. Aerts, et al.
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.
Lancet, 2 (1991), pp. 771-774
[2.]
G. D'Haens, K. Geboes, M. Peeters, F. Baert, F. Penninckx, P. Rutgeerts.
Early lesions caused by infusion of intestinal contents in excluded ileum in Crohn's disease.
Gastroenterology, 114 (1998), pp. 262-267
[3.]
C. Fiocchi.
Inflammatory bowel disease: etiology and pathogenesis.
Gastroenterology, 115 (1998), pp. 182-205
[4.]
R.J. Chiodini, H.J.V. Kruiningen, W.R. Thayer, R.S. Merkal, J.A. Coutu.
Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified mycobacterium species isolated from patients with Crohn's disease.
Dig Dis Sci, 29 (1984), pp. 1073-1079
[5.]
W.R. Thayer, J.A. Coutu, R.J. Chiodinni, H.J.V. Kruiningen, R.S. Merkal.
Possible role of mycobacteria in inflammatory bowel disease (II). Mycobacterial antibodies in Crohn's disease.
Dig Dis Sci, 29 (1984), pp. 1080-1085
[6.]
K. Kobayashi, W.R. Brown, P.L. Brennan, M.J. Blaser.
Serum antibodies to mycobacterial antigens in active Crohn's disease.
Gastroenterology, 94 (1988), pp. 1401-1411
[7.]
K. Kobayashi, M.J. Blaser, W.R. Brown.
Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease.
Gastroenterology, 96 (1989), pp. 1009-1015
[8.]
J.D. Sanderson, M.T. Moss, M.L.V. Tizard, J. Hermon-Taylor.
Mycobacterium paratuberculosis DNA in Crohn's disease tissue.
Gut, 33 (1992), pp. 890-896
[9.]
C. Prantera, A. Kohn, R. Mangiarotti, A. Andreoli, C. Luzi.
Antimycobaacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.
Am J Gastroenterol, 89 (1994), pp. 513-518
[10.]
G.L. Swift, E.D. Srivastava, R. Stone, R.D. Pullan, R.G. Newcombe, J. Rhodes, et al.
Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease.
Gut, 35 (1994), pp. 363-368
[11.]
S. Tabaqchali, D.P. O'Donoghue, K.A. Bettleheim.
Escherichia coli antibodies in patients with inflammatory bowel disease.
Gut, 19 (1978), pp. 108-113
[12.]
A. Darfeuille-Michaud, C. Neut, N. Barnich, E. Lederman, P. Di Martino, P. Desreumaux, et al.
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease.
Gastroenterology, 115 (1998), pp. 1405-1413
[13.]
E. Masseret, J. Boudeau, J.F. Colombel, C. Neut, P. Desreumaux, B. Joly, et al.
Genetically related Escherichia coli strains associated with Crohn's disease.
Gut, 48 (2001), pp. 320-325
[14.]
A.J. Wakefield, E.A. Sankey, A.P. Dhillon, A.M. Sawyer, L. More, R. Sim, et al.
Granulomatous vascultis in Crohn's disease.
Gastroenterology, 100 (1991), pp. 1279-1287
[15.]
A.J. Wakefield, R.M. Pittilo, R. Sim, S.L. Cosby, J.R. Stephenson, A.P. Dhillon, et al.
Evidence of persistent measles virus infection in Croh's disease.
J Med Virol, 39 (1993), pp. 345-353
[16.]
A. Ekbom, A.J. Wakefield, M. Zack, H.O. Adami.
Perinatal measles infection and subsequent Crohn's disease.
Lancet, 334 (1994), pp. 508-510
[17.]
N.P. Thompson, S.M. Montgomery, R.E. Pounder, A.J. Wakefield.
Is measles vaccination a risk factor for inflammatory bowel disease?.
Lancet, 345 (1995), pp. 1071-1074
[18.]
M. Campieri, P. Gionchetti.
Bacteria as the cause of ulcerative colitis.
Gut, 48 (2001), pp. 132-135
[19.]
A. Swidsinski, A. Ladhoff, A. Pernhaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, et al.
Mucosal flora in inflammatory bowel disease.
Gastroenterology, 122 (2002), pp. 44-54
[20.]
J. Braun.
Unsettling facts of life: bacterial commensalism, epithelial adherence and inflammatory bowel disease.
Gastroenterology, 122 (2002), pp. 228-229
[21.]
S. Videla, J. Vilaseca, F. Guarner, A. Salas, F. Treserra, E. Crespo, et al.
Role of intestinal microflora in chronic inflammation and ulceration of the rat colon.
Gut, 35 (1994), pp. 1090-1097
[22.]
S. Videla, J. Vilaseca, F. Guarner, A. Salas, G. González, M. Antolín, et al.
Stimulation of mucosal inflammatory activity by the normal fecal flora in a rat model of colitis.
Inflammatory Bowel Dis, 3 (1997), pp. 191-197
[23.]
A. García-Lafuente, M. Antolín, F. Guarner, E. Crespo, A. Salas, P. Forcada, et al.
Incrimination of anaerobic bacteria in the induction of experimental colitis.
Am J Physiol, 272 (1997), pp. G10-G15
[24.]
M. Mourelle, A. Salas, F. Guarner, E. Crespo, A. García-Lafuente, J.R. Malagelada.
Stimulation of transforming growth factor-ß1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis.
Gastroenterology, 114 (1998), pp. 519-526
[25.]
R. Duchmann, I. Kaiser, E. Hermann, W. Mayet, K. Ewe, K.H. Meyer zum Buschenfelde.
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease.
Clin Exp Immunol, 102 (1995), pp. 448-455
[26.]
R. Duchmann, E. Schmitt, P. Knolle, K.H. Meyer zum Buschenfelde, M. Neurath.
Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interlukin-10 or antibodies to interleuklin-12.
Eur J Immunol, 26 (1996), pp. 934-938
[27.]
R.O. Ehrhardt, B.R. Ludviksson, B. Gray, M. Neurath, W. Strober.
Induction and prevention of colonic inflammation in IL-2-deficient mice.
J Immunol, 158 (1997), pp. 566-573
[28.]
R. Kühn, J. Lohler, D. Rennick, K. Rajewsky, W. Muller.
Interleukin-10-deficient mice develop chronic enterocolitis.
Cell, 75 (1993), pp. 263-274
[29.]
A. Macpherson, U.Y. Khoo, I. Forgacs, J. Philpott-Howard, I. Bjarnason.
Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.
Gut, 38 (1996), pp. 365-375
[30.]
R. Duchmann, M.F. Neurath, K.H. Meyer zum Büschenfelde.
Responses to self and non-self intestinal microflora in health and inflammatory bowel disease.
Res Immunol, 148 (1997), pp. 589-594
[31.]
F. Casellas, N. Borruel, M. Papo, F. Guarner, M. Antolín, S. Videla, et al.
Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis.
Inflamm Bowel Dis, 4 (1998), pp. 1-5
[32.]
B.E. Sands.
Therapy of inflammatory bowel disease.
Gastroenterology, 118 (2000), pp. S68-S82
[33.]
R.J. Dickinson, H.J. O'Connor, I. Pinder, I. Hamilton, D. Johnston, A.T. Axon.
Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis.
Gut, 26 (1985), pp. 1380-1384
[34.]
R.W. Chapman, W.S. Selby, D.P. Jewell.
Controlled trial of intravenous metronidazole as adjunct to corticoids in severe ulcerative colitis.
Gut, 27 (1986), pp. 1210-1212
[35.]
D.A. Burke, A.T. Axon, S.A. Clayden, M.F. Dixon, D. Johnston, R.W. Lacey.
The efficacy of tobramycin in the treatment of ulcerative colitis.
Aliment Pharmacol Ther, 4 (1990), pp. 123-129
[36.]
A.J. Lobo, D.A. Burke, G.M. Sobala, A.T. Axon.
Oral tobramycin in ulcerative colitis: effect on maintenance of remission.
Aliment Pharmacol Ther, 7 (1993), pp. 155-158
[37.]
G.J. Mantzaris, A. Hatzis, P. Kontogiannis, G. Triadaphyllou.
Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.
Am J Gastroenterol, 89 (1994), pp. 43-46
[38.]
P. Gionchetti, F. Rizzello, A. Ferrieri, A. Venturi, C. Brignola, M. Ferretti, et al.
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double blind, placebo-controlled trial.
Dig Dis Sci, 44 (1999), pp. 1220-1221
[39.]
G.J. Mantzaris, E. Archavlis, P. Christoforidis, D. Kourtessas, P. Amberiadis, N. Florakis, et al.
A prospective randomised controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Am J Gastroenterol, 92 (1997), pp. 454-456
[40.]
G.J. Mantzaris, K. Petraki, E. Archavlis, P. Amberiadis, D. Kourtessas, A. Christidou, et al.
A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.
Scand J Gastroenterol, 36 (2001), pp. 971-974
[41.]
U.M. Turunen, M.A. Farkkila, K. Hakala, K. Seppala, A. Sivonen, M. Ogren, et al.
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study.
Gastroenterology, 115 (1998), pp. 1072-1078
[42.]
L. Sutherland, J. Singleton, J. Sessions, S. Hanauer, E. Krawitt, G. Rankin, et al.
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
Gut, 32 (1991), pp. 1071-1075
[43.]
J. Jakobovits, M.M. Schuster.
Metronidazole therapy for Crohn's disease and associated fistulae.
Am J Gastroenterol, 79 (1984), pp. 533-540
[44.]
P. Rutgeers, M. Hiele, K. Geboes, M. Peeters, F. Penninckx, R. Aerts, et al.
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.
Gastroenterology, 108 (1995), pp. 1617-1621
[45.]
J.F. Colombel, M. Lemman, M. Cassagnou, Y. Bouhnik, B. Duclos, J.L. Dupas, et al.
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease.
Am J Gastroenterol, 94 (1999), pp. 674-678
[46.]
S.L. Greenbloom, A.H. Steinhart, G.R. Greenberg.
Combination ciprofloxacin and metronidazole for active Crohn's disease.
Can J Gastroenterol, 12 (1998), pp. 53-56
[47.]
C. Prantera, F. Zannoni, M.L. Scribano, E. Berto, A. Andreoli, A. Kohn, et al.
An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled trial of metronidazole plus ciprofloxacin.
A J Gastroenterol, 91 (1996), pp. 328-332
[48.]
K. Leiper, A.I. Morris, J.M. Rhodes.
Open label trial of oral clarithromycin in active Crohn's disease.
Aliment Pharmacol Ther, 14 (2000), pp. 801-806
[49.]
J.F. Colombel, A. Cortot, H.J. Van Kruiningen.
Antibiotics in Crohn's disease.
Gut, 48 (2001), pp. 647
[51.]
F. Shanahan.
Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.
Gastroenterology, 120 (2001), pp. 622-635
[52.]
J.A. Milner.
Functional foods and health promotion.
J Nutr, 129 (1999), pp. S1395-S1397
[54.]
F. Shanahan.
Probiotics and inflammatory bowel disease: is there a scientific rationale?.
Inflamm Bowel Dis, 6 (2000), pp. 107-115
[55.]
N. Borruel, M. Carol, F. Casellas, M. Antolin, F. De Lara, E. Espin, et al.
Increased mucosal TNFα production in Crohn's disease can be modulated in vitro by probiotic bacteria.
Gut, 5 (2002), pp. 659-664
[56.]
R. Fabia, A. Ar'Rajab, M.L. Johansssib, R. Willen, R. Andersson.
The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-acid induced colitis in the rat.
Scand J Gastroenterol, 28 (1993), pp. 155-162
[57.]
Y. Mao, S. Nobaeck, B. Kasravi, D. Adawi, U. Stenram, G. Molin, et al.
The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats.
Gastroenterology, 111 (1996), pp. 334-344
[58.]
R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, W. Muller.
Interleukin-10 deficient mice develop chronic enterocolitis.
Cell, 75 (1993), pp. 263-274
[59.]
R.K. Sellon, S.L. Tonkonogy, M. Schultz, L.A. Dieleman, W. Grenther, E. Balish, et al.
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice.
Infect Immun, 66 (1998), pp. 5224-5231
[60.]
K.L. Madsen, J.S. Doyle, M.M. Tavernini, L.D. Jewell, R.P. Rennie, R.N. Fedorak.
Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice.
Gastroenterology, 118 (2000), pp. 1094-1105
[61.]
K.L. Madsen, J.S. Doyle, L.D. Jewell, M.M. Tavernini, R.N. Fedorak.
Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.
Gastroenterology, 116 (1999), pp. 1107-1114
[62.]
K. Madsen, A. Cornish, P. Soper, C. Mc Kaigney, H. Jijon, C. Yachimec, et al.
Probiotic bacteria enhance murine and human intestinal epithelial barrier function.
Gastroenterology, 121 (2001), pp. 580-591
[63.]
O'Mahony, M. Feeney, S. O'Halloran, L. Murphy, B. Kiely, J. Fitzgibbon, et al.
Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice.
Aliment Pharmacol Ther, 15 (2001), pp. 1219-1225
[64.]
R.J. Kennedy, M. Hoper, K. Deodhar, S.J. Kirk, K.R. Gardiner.
Probiotic therapy fails to improve gut permeability in a hapten model of colitis.
Scand J Gastroenterol, 35 (2000), pp. 1266-1271
[65.]
L. Steidler, W. Hans, L. Schotte, S. Neirynck, F. Obermeier, W. Falk, et al.
Treatment of murine collitis by Lactococcus lactis secreting interleukin-10.
Science, 289 (2000), pp. 1352-1355
[66.]
F. Shanahan.
Turbo probiotics for IBD.
Gastroenterology, 120 (2001), pp. 1297-1298
[67.]
S. Videla, J. Vilaseca, M. Antolin, A. Garcia-Lafuente, F. Guarner, E. Crespo, et al.
Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat.
Am J Gastroenterol, 96 (2001), pp. 1486-1493
[68.]
M. Malin, H. Soumalainen, M. Saxelin, E. Isolauri.
Promotion of Ig A immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG.
Ann Nutr Metab, 40 (1996), pp. 137-145
[69.]
P. Gupta, H. Andrew, B.S. Kirschner, S. Guandalini.
Is Lactobacillus GG helpful in children with Crohn's disease?.
Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr, 31 (2000), pp. 453-457
[70.]
K. Plein, J. Hotz.
Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea.a pilot study.
Z Gastroenterol, 31 (1993), pp. 129-134
[71.]
M. Guslandi, G. Mezzi, M. Sorghi, P.A. Testoni.
Saccharomyces boulardii in maintenance treatment of Crohn's disease.
Dig Dis Sci, 45 (2000), pp. 1462-1464
[72.]
W. Kruis, E. Schutz, P. Fric, B. Fixa, G. Judmaier, M. Stolte.
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther, 11 (1997), pp. 853-858
[73.]
B.J. Rembacken, A.M. Snelling, P.M. Hawkey, D.M. Chalmers, A.T. Axon.
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Lancet, 354 (1999), pp. 635-639
[74.]
W.A. Faubion, W.J. Sandborn.
Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
Gastroenterology, 118 (2000), pp. 630-631
[75.]
P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, et al.
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gastroenterology, 119 (2000), pp. 305-309
[76.]
A. Venturi, P. Gionchetti, F. Rizzello, R. Johansson, E. Zucconi, P. Brigidi, et al.
Impact on the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.
Aliment Pharmacol Ther, 13 (1999), pp. 1103-1108
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
